【摘要】 Dostarlimab是一种抗程序性死亡受体1(anti-PD-1)阻断抗体，用于治疗DNA错配修复功能缺陷（dMMR）的晚期或复发性实体瘤成人患者，这些患者在先前治疗后病情进展，且没有令人满意的替代治疗方案。dMMR状态是一种可以预测肿瘤对免疫检查点抑制剂反应的有效生物标志物，其在子宫内膜癌、胃癌、结直肠癌等实体瘤中发病率较高。本文就Dostarlimab的药理作用及作用机制、药物代谢动力学、临床疗效和安全性评价等进行综述。更多还原

【Abstract】 Dostarlimab is an anti-programmed death-1(anti-PD-1)blocking antibody for adult patients with advanced or recurrent solid tumors with mismatch repair deficient(dMMR)who have progressed after prior therapy and have no satisfactory alternative treatment options. dMMR is an effective biomarker that can predict tumor response to immune checkpoint inhibitors,and its incidence is high in endometrial cancer,gastric cancer,colorectal cancer,and other solid tumors. The mechanism of action,pharmacokinetics,clinical efficacy and safety evaluation of Dostarlimab were reviewed in this paper.更多还原